APA (7th ed.) Citation

Faehling, M., Schumann, C., Christopoulos, P., Hoffknecht, P., Alt, J., Horn, M., . . . Christoph, D. C. (2020). Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP). Lung cancer, 150(12), . https://doi.org/10.1016/j.lungcan.2020.10.006

Chicago Style (17th ed.) Citation

Faehling, Martin, et al. "Durvalumab After Definitive Chemoradiotherapy in Locally Advanced Unresectable Non-small Cell Lung Cancer (NSCLC): Real-world Data on Survival and Safety from the German Expanded-access Program (EAP)." Lung Cancer 150, no. 12 (2020). https://doi.org/10.1016/j.lungcan.2020.10.006.

MLA (9th ed.) Citation

Faehling, Martin, et al. "Durvalumab After Definitive Chemoradiotherapy in Locally Advanced Unresectable Non-small Cell Lung Cancer (NSCLC): Real-world Data on Survival and Safety from the German Expanded-access Program (EAP)." Lung Cancer, vol. 150, no. 12, 2020, https://doi.org/10.1016/j.lungcan.2020.10.006.